Financing, Equity Capital Markets

Acelyrin, Inc.

05/23
|
$621.0 Million
Acelyrin
Piper Sandler served as bookrunner for Acelyrin, Inc. on its initial public offering
Sub-Type
IPO
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
Northpointe
Northpointe Bancshares, Inc.
Subordinated Notes Offering
Sole Placement Agent
$150.0 Million
EverBank
EverBank Financial Corp.
Subordinated Notes Offering
Sole Underwriter
miax
warburg pincus
Miami International Holdings, Inc.
Miami International Holdings, Inc received a strategic growth investment from Warburg Pincus
Financial Advisor
$42.0 Million
Trinitas
Trinitas Capital Management, LLC
Senior Unsecured Notes Offering
Sole Placement Agent
$103.2 Million
Merchants Bancorp
Merchants Bancorp
Confidentially Marketed Follow-On Offering
Passive Bookrunner
$70.0 Million
CereVasc
Bain
Xontogeny
CereVasc, Inc.
CereVasc, Inc. has received a Series B Financing from Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund (PXV)

Financial Advisor
$225.0 Million
Provident Financial Services, Inc.
Provident Financial Services Inc.
Subordinated Notes Offering
Left Bookrunner
$184.7 Million
Skyward Specialty Insurance
Skyward Specialty Insurance
Follow-On Offering
Passive Bookrunner
$100.0 Million
Context Therapeutics LLC
Context Therapeutics LLC
PIPE
Sole Placement Agent
$50.0 Million
Legion
Riverwood
Legion Technologies, Inc.
Legion Technologies, Inc. has received a growth investment from Riverwood Capital Management L.P.
Financial Advisor
$201.2 Million
Nurix Inc.
Nurix Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$150.0 Million
Blue Ridge Bankshares
Blue Ridge Bankshares, Inc.
PIPE
Sole Placement Agent
$200.0 Million
Praxis Precision Medicines
Praxis Precision Medicines, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$100.0 Million
Boundless Bio, Inc.
Boundless Bio, Inc.
Initial Public Offering
Active Bookrunner
$75.0 Million
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$600.0 Million
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner

© 2024 Piper Sandler Companies. Since 1895. All rights reserved.